Business
Prestige Consumer Healthcare, Inc. (PBH) Securities Fraud Investigation - Levi & Korsinsky
Prestige Consumer Healthcare, Inc. (PBH) Securities Fraud Investigation - Levi &
About this update from Prestige Consumer Healthcare Inc.
[{"type":"text","content":" Prestige Consumer Healthcare shares fell sharply after Q4 earnings missed consensus estimates -- adjusted EPS came in at $1.23 versus the $1.39 expected, driven by unresolved supply-chain constraints management had assured investors were improving. NEW YORK, May 22, 2026 /PRNewswire/ -- Prestige Consumer Healthcare, Inc. (NYSE: PBH) investors suffered significant losses when the stock dropped after the Company reported Q4 fiscal 2026 earnings well below expectations, with adjusted EPS of $1.23 versus the $1.39 consensus estimate and revenue of $281.6 million falling short of forecasts. If you lost money on your PBH investment, submit your information here to discuss your legal rights . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.The investigation concerns whether Prestige Consumer Healthcare adequately disclosed risks to its Clear Eyes product supply chain during the quarters leading up to the Q4 miss. On the Company's Q3 fiscal 2026 earnings call, CEO Ron Lombardi stated the Company was \"positioned to continue to improve supply sequentially again in Q4 and moving forward,\" while CFO Christine Sacco told investors to \"anticipate a 57% adjusted gross margin in Q4.\" The Q4 results revealed those targets were not met, and the supply-chain remediation that management had repeatedly characterized as on track had not been completed.The Company had guided investors toward full-year adjusted diluted EPS of approximately $4.54 and revenues of $1.1 billion. On the Q2 earnings call, CEO Lombardi stated the Company was \"on track to improve Clear Eyes supply in the second half\" and expected \"a second-half improvement in eye-care supply previously discussed that underpins our full-year forecast.\" The gap between those assurances and the Q4 outcome is now the subject of Levi & Korsinsky's investigation into potential securities law violations.Shareholders who purchased PBH and suffered losses are encouraged to click here to submit their information before the investigation concludes. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has e...